Department of Pediatrics, Columbia University Irving Medical Center, Columbia University, New York, NY.
Department of Psychiatry, Columbia University Irving Medical Center, Columbia University, New York, NY.
Genet Med. 2022 Sep;24(9):1878-1887. doi: 10.1016/j.gim.2022.06.002. Epub 2022 Jun 29.
The knowledge used to classify genetic variants is continually evolving, and the classification can change on the basis of newly available data. Although up-to-date variant classification is essential for clinical management, reproductive planning, and identifying at-risk family members, there is no consistent practice across laboratories or clinicians on how or under what circumstances to perform variant reinterpretation.
We conducted exploratory focus groups (N = 142) and surveys (N = 1753) with stakeholders involved in the process of variant reinterpretation (laboratory directors, clinical geneticists, genetic counselors, nongenetic providers, and patients/parents) to assess opinions on key issues, including initiation of reinterpretation, variants to report, termination of the responsibility to reinterpret, and concerns about consent, cost, and liability.
Stakeholders widely agreed that there should be no fixed termination point to the responsibility to reinterpret a previously reported genetic variant. There were significant concerns about liability and lack of agreement about many logistical aspects of variant reinterpretation.
Our findings suggest a need to (1) develop consensus and (2) create transparency and awareness about the roles and responsibilities of parties involved in variant reinterpretation. These data provide a foundation for developing guidelines on variant reinterpretation that can aid in the development of a low-cost, scalable, and accessible approach.
用于对遗传变异进行分类的知识在不断发展,并且新出现的数据可能会改变分类。虽然及时更新变异分类对于临床管理、生殖计划以及识别高危家族成员至关重要,但实验室或临床医生在如何以及在什么情况下进行变异重新解读方面,没有一致的做法。
我们对参与变异重新解读过程的利益相关者(实验室主任、临床遗传学家、遗传咨询师、非遗传提供者和患者/父母)进行了探索性焦点小组(N=142)和调查(N=1753),以评估关键问题的意见,包括重新解读的启动、要报告的变异、重新解读责任的终止以及对同意、成本和责任的担忧。
利益相关者普遍认为,重新解读先前报告的遗传变异的责任不应有固定的截止点。对责任的担忧和对许多变异重新解读的后勤方面的共识不足。
我们的研究结果表明,有必要(1)达成共识,(2)提高对变异重新解读中各方的角色和责任的透明度和认识。这些数据为制定变异重新解读指南提供了基础,有助于开发一种低成本、可扩展和可及的方法。